Progress in the Clinical Management of Haemophilia

• References

• 1 Bloom AL. The evolution and future of haemophilia Therapy. Transfusion Medicine 1991; 1: 5-12
• 2 Roberts HR, Macik BG. Factor VIII and IX concentrates: Clinical efficacy as related to purity. In Thrombosis and Haemostasis.. Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds) International Society on Thrombosis and Haemostasis and Leuven University Press, Leuven: 1987: pp563-581
• 3 Heimburger N, Schwinn H, Gratz P, Luben G, Kumpe G, Herchenhahn B. A factor VIII concentrate highly purified and heat treated in solution. Arzneim-Forsch. 1981; 41: 619-622
• 4 Schimpf K, Mannucci PM, Kreutz W. et al. Absence of hepatitis after treatment with a pasteurised factor VIII concentrate in patients with haemophilia and no previous transfusions. N Engl J Med 1987; 316: 918-922
• 5 Heinrich D. Kotitsche R, Berthold H. Clinical evaluation of the hepatitis safety of a β-propialactone/ultraviolet treated factor IX concentrate (PPSB). Thromb Res 1982; 28: 75-83
• 6 Kleim JP, Bailly E, Schneweis KE. et al. Acute HIV-1 infection in patients with hemophilia B treated with (3-propiolactone - UV - inactivated clotting factor. Thrombos Haemostas 1990; 64: 336-337
• 7 Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right?. J Amer Med Assoc 1983; 249: 1743-1745
• 8 Mannucci PM, Colombo B. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemostas 1989; 61: 552-534
• 9 Mannucci PM, Zanetti AR, Colombo M. et al. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. Thrombos Haemostas 1990; 64: 232-234
• 10 Mannucci PM, Schimpf K, Brettler DB. et al. Low risk for hepatitis C in hemophiliacs given high purity, pasteurised factor VIII concentrates. International study group. Ann Intern Med 1990; 113: 27-32
• 11 Berntorp E, Nilsson I-M, Ljung R, Widdell A. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet 1990; 335: 1531-1532
• 12 Kuo G, Choo Q-L, Alter HJ. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364
• 13 Alter HJ, Purcell RH, Shih JW. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500
• 14 Esteban JI, Esteban R, Vicadomiu L. et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; ii: 294-297
• 15 Roggendorf M, Deinhardt F, Rabshofer R. et al. Antibodies to hepatitis C virus.. Lancet 1989; ii: 324-325
• 16 Noel L, Guerois C, Maisonneuve P. et al. Antibodies to hepatitis C virus in haemophilia. Lancet 1989; ii: 56
• 17 Ludlam CA, Chapman D, Cohen B, Litton PA. Antibodies to hepatitis C virus in haemophilia. Lancet 1989; ii: 560-561
• 18 Makris M, Preston FE, Triger DR. et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990; 335: 1117-1119
• 19 Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FGH. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med. Virol. 1990; 30: 50-52
• 20 Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, Parker D, Barbara JAJ, Contreras M, Aloysius S. Detection of hepatits C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity. Lancet 1991; 335: 1419-1422
• 21 Garson JA, Preston FE, Makris M, Tuke P, Ring C, Machin SJ, Tedder RS. Detection by PCR of hepatitis C virus in factor VIII concentrates. Lancet 1990; 335: 147
• 22 Simmonds P, Zhang LQ, Watson HG. et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990; 336: 1469-1472
• 23 Garson JA, Tuke PW, Makris M. et al. Demonstration of viraemia patterns in haemophilics treated with hepatitis C virus-contaminated factor VIII concentrates. Lancet 1990; 336: 1022-1025
• 24 Van der Pool CL, Reesink HW, Schaasberg W. et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990; 335: 558-560
• 25 Editorial The A to F of viral hepatitis. Lancet 1990; 336: 1158-1160
• 26 MMWR Safety of therapeutic products used for haemophilic patients. Morbidity and Mortality Weekly Reports 1988; 37: 441-450
• 27 Loche M, Mach B. Identification of HIV-infected seronegative individuals by a direct diagnostic test based on hybridisation to amplified viral DNA. Lancet 1988; ii: 418-421
• 28 Gibbons J, Cory JM, Hewlett IK. et al. Silent infections with human immunodefficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs. Blood 1990; 76: 1924-1926
• 29 Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfer of blood components that test antibody-negative. N Engl J Med 1989; 321: 941-946
• 30 Donahue JG, Nelson KE, Yawn DH. et al. Transmission of HIV by transfusion of screened blood. N Engl J Med 1990; 323: 170
• 31 Lyon DJ, Chapman CS, Martin C. et al. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; i: 10
• 32 Madhok R, Gracie A, Lowe GDO. et al. Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Brit Med J 1986; 293: 978-980
• 33 Mannhalter JW, Ahmad R, Leibl H. et al. Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity. Blood 1988; 71: 1662-1668
• 34 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates : A possible cause of immunosuppression in haemophiliacs. Brit. J Haemat 1989; 71: 387-39
• 35 Schreiber AB, Gillette R, Hrindra ME. in vitro parameters of Monoclate, a monoclonal antibody purified human plasma factor VIIIC therapeutic preparation.. Thromb Haemostas 1989; 58: 34 (Abst)
• 36 Eibl MM, Ahmad R, Wolf HM. et al. A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions. Blood 1989; 69: 1153-1160
• 37 Rizza CR, Spooner RTD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: Report on behalf of the directors of haemophilia centres in the United Kingdom. Brit Med J 1983; 286: 929-933
• 38 Aronson DL. Cause of death in haemophilia A patients in the United States from 1968 to 1979. Amer J Haematol 1988; 27: 7-12
• 39 Ludlam CA, Tucker J, Steel CM. et al. Human T-lymphotropic virus type III (HTLVIII) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985; ii: 233-236
• 40 Beddal AC, Hill FGH, George RH, Williams MD, Al-Rubei K. Usually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital. J Clin Pathol 1985; 38: 1163-1165
• 41 Goodall A. Is immune dysfunction in HIV seronegative haemophilic patients caused by HCV. Workshop: Blood products and immune-dysfunction,. Liverpool, England: 1991
• 42 Brettler DB, Forsberg AD, Levine PH. et al. Factor VIII:C concentrate purified from plasma using monoclonal antibodies : Human studies. Blood 1989; 73: 1859-1863
• 43 Rocino A, de Biasi R. Prospective controlled trial of an ultra-pure factor VIII concentrate to evaluate the effects on immune status (preliminary results). Workshop : Blood products and immune-dysfunction,. Liverpool, England: 1991
• 44 Brettler DB. Proposed protocol for the evaluation of the effect of high purity factor concntrates on the immune system of hemophilia patients. Thromb. Haemostas 1989; 62: 811-812
• 45 Kasper CK. Clinical use of factor IX concentrates: Report on thromboembolic complications. Thromb. Diath. haemorrh 1975; 33: 640-644
• 46 Menache D, Behre HE, Orthner CL. et al. Coagulation factor IX concentrate : Method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-1227
• 47 Burnouf T, Michalski E, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX : C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232
• 48 Kim HC, McMillan CW, White GC. et al. Clinical experience of a new monoclonal antibody purified factor IX ; Half-life recovery and safety in patients with hemophilia B.. Seminars in Hemat 1990; 27 (Suppl 2) 30-35
• 49 Mannucci PM, Bauer KA, Gringeri A. et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-2545
• 50 Menache D. New concentrates of factors VII, IX and X. In Recent Advances in Hemophilia Care. 1990. Alan R Liss Inc New York: pp 177-187
• 51 Bardin JM, Sultan Y. Factor IX concentrate versus prothrombin complex concentrate for treatment of hemophilia B during surgery. Transfusion 1990; 30: 441-443
• 52 Lorand L, Losowsky MS, Miloszewski KJM. Human factor XIII; Fibrin stabilising factor. Progr. Haemostas Thromb 1980; 5: 245-290
• 53 Cattaneo M, Moia M, Valle PD. et al DDA VP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Brit. J Haemat 1989; 74: 1972-1975
• 54 Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000
• 55 Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; ii: 675-676
• 56 Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrands disease. Vox Sang 1989; 56: 212-217
• 57 Fukui H, Nishino M, Terada S. et al. Hemostatic effect of a heat-treated factor VIII concentrate (Hemate P) in von Willebrands disease. Blut 1988; 56: 171-178
• 58 Rose E, Forster A, Aledort LM. Correction of prolonged bleeding time in von Willebrands disease with Humate P. Transfusion 1990; 30: 38
• 59 Cumming AM, Fildes S, Cumming IR. et al. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand disease. Brit J Haemat 1990; 75: 234-239
• 60 Pasi KJ, Williams MD, Enayat MS. Clinical and laboratory evaluation of the treatment of von Willebrands disease patients with heat-treated factor VIII concentrate (BPL8Y). Brit J Haemat 1990; 75: 228-233
• 61 Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. in vitro and in vivo characterisation of high-purity, solvent/detergent treated factor VIII concentrate: Evidence for its therapeutic efficacy in von Willebrand's disease. Europ J Haematol 1989; 43: 7-14
• 62 Delvos U, Novakova-Banet A, Freudenberg W, Heimburger N. The factor VIII complex : biochemical properties, clinical data, and safety profile of factor VIII:CP and von Willebrand factor Behring. Proc 6th Int Symp Hem Treat. 1990; 6: 65-74
• 63 Lusher JM, Salzman PM. and the Monoclate Study Group Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Sem Hemat 1990; 27 Suppl 2 1-7
• 64 Bell BA, Kerczynski EM, Bergman G. Inhibitors to monoclonal antibody purified factor VIII. Lancet 1990; 336: 63
• 65 Kessler CM, Sachse K. Factor VIII; C inhibitor associated with monoclonal-antibody purified factor VIII concentrate. Lancet 1990; 335: 140
• 66 Wood WI, Capon DJ, Simonsen CC. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-336
• 67 Toole JJ, Knopf JL, Wozey JM. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
• 68 Giles AR, Tinlin S, Hoogedoorn H. et al. in vivo characterisation of recombinant factor VIII in a canine model of haemophilia A (factor VIII deficiency). Blood 1988; 72: 335-339
• 69 White GCII, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-170
• 70 Schwartz RS, Abilgaard CF, Aledort LM. et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med 1990; 323: 1800-1805
• 71 Harrison JFM, Bloom AL, Abilgaard CF. The pharmacokinetics of recombinant factor VIII. Semin Hemat 1991 (in press)
• 72 Bloom Al, Harrison JFM, Allred R. et al. in vivo recovery and pharmacokinetic studies of recombinant factor VIII (rFVIII) in haemophilic patients by model dependent and independent analysis. 13th. Int Cong Thromb Haemostas 1991; Thromb Haemostas 1991 (in press)
• 73 Mondorf W, Scharrer I. Lack of inhibitor to monoclonal antibody purified FVIII concentrate. Lancet 1990; 336: 74
• 74 Bloom AL. The treatment of factor VIII inhibitors. Thrombosis and Haemostasis.. Verstraete M, Vermylen J, HR Lijnen, Arnout J. (Eds) Int Soc Haem Thromb and Leuven University Press, Leuven: 1987. pp 447-471
• 75 Kasper CK. Treatment of factor VIII inhibitors. Progr Haemostas. Thromb 1989; 9: 57-86
• 76 Hilgartner M, Aledort L, Andes A. Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-630
• 77 Barrowcliffe TW, Kemball-Cooke G, Grey E. Factor VIII inhibitor by passing activity : A suggested mechamism of action. Thrombosis Res 1981; 21: 181-186
• 78 Yoshioka A, Peake IR, Furlong BL. et al. The interaction between factor VIII clotting antigen (FVIIICAg) and phospholipid. Brit J Haemat 1983; 55: 27-36
• 79 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine resides bypasses factor VIII in vivo. Brit J Haemat. 1988; 69: 491-497
• 80 Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high titer inhibitors. J Clin Invest 1983; 71: 1836-1841
• 81 Hedner U, Bjoern S, Bemvil SS. et al. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titre inhibitors. Haemostasis 1989; 19: 335-343
• 82 Chabbat J, Hampikian-Lenin S, Toully Y. et al. A human factor VIIa concentrate and its effects in the hemophilia A dog. Thromb Res 1989; 54: 603-612
• 83 Thim L, Bjoern S, Christensen M. et al. Amino acid sequence and post-translational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793
• 84 Hedner U, Glazer S, Pingel K. et al. Sucessful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; ii: 119
• 85 Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a hemophilic patient with a high titer inhibitor. Amer J Haematol 1989; 32: 232-234
• 86 Harrison JFM, Bloom AL. Pharmacokinetics and coagulation changes after administration of recombinant human activated factor VII(rVIIa NOVO).. Proc Brit Soc Haem. 1991; Brit J Haem 1991 (in press)
• 87 Harrison JF, Fegan C, Dasani H, Bloom AL. Clinical effect of recombinant human activated factor VII(rFVIIa NOVO).. Proc Brit Soc Haemat 199. Brit J Haem 1991 (in press)
• 88 Telgt DSC, Macik BG, McCord DM. et al. Mechanism by which recombinant factor VIIa shortens the aPTT; Activation of factor X in the absence of tissue factor. Thromb Res 1989; 56: 603-609
• 89 Roa LVM, Rapaport SI. Factor VIIa - catalysed activation of factor X independent of tissue factor: Its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75: 1069-1073
• 90 Stein SF, Duncan A, Cutler D, Glazer S. Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor VIIa.. Blood 1990; 76 Suppl 1 438a
• 91 Bontempo FA, Lewis JH, Goreng TJ. et al. Liver transplant in hemophilia A. Blood 1987; 69: 1721-1724
• 92 Clark aj, Bessos H, Bishop JO. Expression of human antihaemophilic factor IX in the milk of transgenic sheep. Biotechnology 1989; 7: 487-492
• 93 Palmer TD, Thompson AR, Miller Ad. . Blood 1989; 73: 438-445
• 94 Hay CRM, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL-2-receptor expression by factor VIII concentrate : A possible cause of immunosuppression in haemophiliacs. Brit J Haemat 1990; 75: 278-281